Pure Global: Chile's MedTech Surprise - Cracking Decree 25's Hidden Regulatory Hurdles.

This week on LATAM MedTech Insights, we dissect the impactful new regulations quietly introduced in Chile. Exempt Decree No. 25 has significantly expanded the oversight of the national health authority, the ISP, reshaping the compliance landscape for many medical device manufacturers who previously had an easier path to market. We dive into the specifics of what this decree means for your product portfolio, the new registration and surveillance demands you need to be aware of, and the broader implications for the Latin American MedTech market. This is a critical update for anyone operating in or planning to enter Chile. A specific case involves a US-based diagnostics company that saw its projected launch timeline in Chile triple overnight. Their devices, once subject to a simple notification process, are now under the full scope of Decree 25, requiring a comprehensive regulatory submission they were completely unprepared for, jeopardizing their entire regional expansion plan. Key Takeaways: - What is Chile's Exempt Decree No. 25 and which devices does it suddenly affect? - How does this change impact time-to-market and costs for MedTech companies? - Is your current product portfolio compliant with the ISP's newly expanded oversight? - Why is this seemingly small decree a major signal for the entire LATAM region's regulatory future? - What are the three immediate steps you must take to de-risk your Chilean market strategy? - How can you leverage your existing technical documentation for the new requirements? - Could these stricter rules actually create a competitive advantage for well-prepared companies? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.